Merck's PAH drug WINREVAIR cuts clinical worsening risk by 76% in early use
PositiveFinancial Markets

Merck's new drug WINREVAIR has shown promising results in clinical trials, reducing the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH) by an impressive 76% when used early. This breakthrough is significant as it offers hope for better management of PAH, a condition that severely impacts patients' quality of life. The findings could lead to improved treatment protocols and better outcomes for those affected by this challenging disease.
— Curated by the World Pulse Now AI Editorial System